Applications of Tissues in Autologous Cell Treatment

Riso Martin^*
*Correspondence: Riso Martin, Department of Bioprocessing, University of Oxford, Oxford OX3 7DQ, UK, Email:

Introduction

Autologous cell therapy, a cutting-edge field in regenerative medicine, involves the use of a patient's own cells to treat various diseases and conditions. This personalized approach offers advantages such as reduced risk of immune rejection and improved therapeutic efficacy. However, the successful delivery and engraftment of autologous cells remain significant challenges. Membrane-based technologies have emerged as promising tools to address these challenges and enhance the outcomes of autologous cell therapy. In this article, we will explore the diverse applications of membranes in autologous cell therapy, including cell encapsulation, cell separation, and immunomodulation. We will discuss recent advancements in membrane technology and their potential implications for improving the efficacy and safety of autologous cell-based therapies [1].

Cell encapsulation involves the confinement of therapeutic cells within semipermeable membranes, allowing for controlled release of therapeutic factors and protection of the cells from host immune responses. Membrane-based encapsulation technologies provide an ideal microenvironment for the survival, function, and integration of transplanted cells. These membranes are designed to regulate the diffusion of oxygen, nutrients, and waste products, thereby maintaining the viability and functionality of encapsulated cells [2].

One notable application of cell encapsulation is in pancreatic islet transplantation for the treatment of type 1 diabetes. Membrane-based encapsulation devices act as immune barriers, preventing immune cells from attacking the transplanted islets while allowing the passage of glucose and insulin. This approach has shown promising results in preclinical and clinical studies, reducing the need for immunosuppressive drugs and improving longterm graft survival. In addition to islet transplantation, membrane encapsulation has been explored for other cell types, such as mesenchymal stem cells (MSCs) and neural progenitor cells. Encapsulated MSCs have been investigated for their potential in regenerative medicine, as the membranes can shield the cells from hostile microenvironments, enhance paracrine effects, and improve their therapeutic efficacy. Similarly, encapsulation of neural progenitor cells has shown promise in treating neurodegenerative disorders, providing a protective barrier and controlled release of neurotrophic factors. Cell separation is a critical step in autologous cell therapy to isolate specific cell populations for therapeutic purposes. Membrane-based separation techniques offer advantages such as simplicity, scalability, and compatibility with clinical applications. Membranes with defined pore sizes and surface properties can selectively retain or exclude cells based on their size, charge, or surface markers [3].

Description

One widely used membrane separation technique is size exclusion filtration, which separates cells based on their size. This approach is valuable in isolating cell subpopulations, such as hematopoietic stem cells, from complex cell mixtures. By employing membranes with specific pore sizes, cells of desired dimensions can be retained while smaller or larger cells are eliminated. Another membrane-based separation method is affinity-based separation, which exploits specific interactions between cell surface markers and ligands immobilized on membranes. This technique enables the isolation of target cells expressing particular markers, such as immune cells or circulating tumor cells. Membrane-based affinity separations offer high specificity and purity, facilitating downstream applications in cancer diagnostics, cell-based immunotherapies, and personalized medicine. Immunomodulation plays a crucial role in autologous cell therapy to regulate immune responses and promote the survival and function of transplanted cells. Membrane-based approaches offer unique opportunities for immunomodulation by incorporating immunomodulatory factors or functionalizing the membrane surface to modulate immune cell behavior [4].

Membranes can be engineered to release immunomodulatory agents in a controlled manner. By incorporating molecules such as anti-inflammatory cytokines or immunosuppressive drugs, membranes can create an immunosuppressive microenvironment around the transplanted cells, reducing the risk of immune rejection. These membranes can also be designed to provide sustained release of growth factors or chemokine, promoting tissue regeneration and modulating immune cell recruitment [5].

Conclusion

Furthermore, membranes can be modified with specific surface coatings or functionalized with immune cell-targeting ligands. These modifications enable the selective interaction with immune cells, directing their behavior towards a tolerogenic phenotype or enhancing their immunosuppressive properties. Such membrane-based immunomodulatory strategies hold promise for enhancing the safety and efficacy of autologous cell therapies in various disease contexts, including autoimmune disorders and solid organ transplantation. Membranebased technologies have emerged as powerful tools in autologous cell therapy, offering versatile applications in cell encapsulation, cell separation, and immunomodulation. These advancements have the potential to improve the delivery, survival, and therapeutic outcomes of autologous cell-based therapies. As researchers continue to refine membrane materials, fabrication techniques, and functionalization strategies, the future of autologous cell therapy appears promising. With further development and translation into clinical practice, membrane-based approaches will likely contribute significantly to the advancement of regenerative medicine and personalized therapies.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Wood, Fiona, Lisa Martin, D. Lewis and J. Rawlins, et al. "A prospective randomised clinical pilot study to compare the effectiveness of biobrane® synthetic wound dressing, with or without autologous cell suspension, to the local standard treatment regimen in paediatric scald injuries." Burns 38 (2012): 830-839.

Google Scholar, Crossref, Indexed at

2. Wahlig, Stephen, Gary SL Peh, Khadijah Adnan and Heng-Pei Ang, et al. "Optimisation of storage and transportation conditions of cultured corneal endothelial cells for cell replacement therapy." Sci Rep 10 (2020): 1-14.

Google Scholar, Crossref, Indexed at

3. Massie, Isobel, Clare Selden, Humphrey Hodgson and Barry Fuller. "Storage temperatures for cold-chain delivery in cell therapy: A study of alginate-encapsulated liver cell spheroids stored at− 80 C or− 170 C for up to 1 year." Tissue Eng Part C Methods 19 (2013): 189-195.

Google Scholar, Crossref, Indexed at

4. Namdaroğlu, Sinem, Emre Tekgündüz, Sinem Civriz Bozdağ and Gamze Durgun, et al. "Microbial contamination of hematopoietic progenitor cell products." Transfus Apher Sci 48 (2013): 403-406.

Google Scholar, Crossref, Indexed at

5. Kozlowska-Skrzypczak, M., E. Bembnista, A. Kubiak and P. Matuszak, et al. "Microbial contamination of peripheral blood and bone marrow hematopoietic cell products and environmental contamination in a stem cell bank: A single-center report." Transplant Proc (2014): 2873-2876.

Google Scholar, Crossref, Indexed at